JNJ Johnson & Johnson Loading...

From ABBV earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
14:00
Feb 04 ◎
Rob Michael Chairman and Chief Executive Officer, AbbVie Inc. ABBV Q4 FY25 call
Skyrizi and Rinvoq combined 2026 sales guidance of $31B+ already surpasses the 2027 long-term goal of $30.5B, implying faster-than-expected immunology growth. — This suggests AbbVie is gaining share faster than expected in key indications (psoriasis, IBD), pressuring competitors like Eli Lilly (Omvoh) and J&J (Tremfya, Stelara).
JNJ
MED

About JNJ Analyst Coverage

Buzzberg tracks JNJ (Johnson & Johnson) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Rob Michael.